This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Wednesday's Health Winners & Losers

Lackluster earnings bogged down a number of health stocks midweek, while others found solace in regulatory approvals and clinical data.

GlaxoSmithKline (GSK - Get Report) reported a disappointing quarter, facing tough generic competition in the U.S. and a decrease in sales of its diabetes drug Avandia. For the three months ended Sept. 30, GlaxoSmithKline said net profit fell 6% year over year to $2.68 billion, while revenue fell 2% to $11.02 billion.

In light of results, GlaxoSmithKline also announced a $3.1 billion program to cut costs, beef up research and development and streamline manufacturing. The company estimates this will result in annual pretax cost savings of up to $1.4 billion by 2010. It expects 40% of the $1.4 billion savings to come from manufacturing, 40% in sales and administration, and 20% in research and development -- though it didn't give a job-cut figure.

Shares fell 89 cents, or 1.7%, to $51.19. The stock is a component of the Amex pharmaceutical index, which edged down 3.35, or 1%, to 343.45.

Also on the decline was Illumina (ILMN - Get Report), which said non-GAAP third-quarter earnings fell 12.8% to 34 cents a share. It beat Street estimates but fell in after-hours trading and then gave up $4.19, or 6.7%, to $58.19 in recent trading Wednesday. Looking ahead, the company raised fourth-quarter guidance to non-GAAP net income of $19 million to $21 million, or 32 cents a share to 35 cents a share.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ABI $22.98 1.01%
ONCY $0.28 3.36%
GSK $39.13 0.00%
ILMN $138.70 0.00%
AAPL $94.27 0.00%


Chart of I:DJI
DOW 15,914.74 -99.64 -0.62%
S&P 500 1,851.86 -0.35 -0.02%
NASDAQ 4,283.5920 +14.8290 0.35%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs